Orsini, a leader in rare disease pharmacy solutions, announced a new partnership with PicnicHealth, a health technology company dedicated to simplifying observational research. This collaboration enables rapid development of drug-specific registries that combine real world drug data, curated electronic medical records (EMR) and patient-reported perspectives. The result is more comprehensive real-world data on approved therapies, providing deeper insights into patient treatment journeys and medication adherence to improve care for rare disease patients.
HealthTech Insights: AI in Healthcare: Light-it and Puppeteer Set a New Standard for Patient Care and Efficiency
In 2024, PicnicHealth launched its life sciences research product to simplify observational research and enable life sciences companies to meet study endpoints. Built on world-class artificial intelligence (AI), PicnicHealth goes directly to consented patients to access their universal patient records and capture relevant study data. This approach enables the rapid creation of drug-specific registries that integrate real-world drug data, curated EMR, and patient-reported outcomes, driving more efficient research and better patient outcomes.
HealthTech Insights: Grove Secures $4.9 Million to Transform Clinical Trials with Agentic AI
Similarly, Orsini recently launched ORBIT™ (Orsini Rare Business Intelligence Technology), an AI-powered reporting and analytics platform designed to enhance care for rare disease patients. By combining their expertise, PicnicHealth and Orsini will generate meaningful insights on patient adherence and long-term outcomes, driving the success of specialized therapies within rare disease populations.
HealthTech Insights: Renown Health selects NRC Health as partner to enhance patient experience and operational efficiency
To launch this venture, Orsini and PicnicHealth will partner with AstraZeneca, a global, science-led biopharmaceutical company, to gather insights on WAINUA™ (eplontersen). Orsini is the exclusive specialty pharmacy partner for WAINUA,* an FDA-approved treatment for adults living with hereditary transthyretin-mediated amyloid polyneuropathy.
HealthTech Insights: Tone by NextSense Debuts First-of-its-Kind Biosensing Smart Earbud at CES 2025
“We are thrilled to partner with PicnicHealth to gain a deeper understanding of patient adherence through real-world data and to work with AstraZeneca to bring these powerful insights to hATTR-PN patients,” said Brandon Tom, Orsini’s Chief Executive Officer. “Adherence is a critical factor to help ensure successful patient outcomes, particularly in rare disease communities. This partnership is another step forward in our mission to leave no patient behind.”
HealthTech Insights: Milliman Report Concludes Together Senior Health’s RADAR Algorithm Accurately Identifies Undiagnosed Cognitive Impairment
“Finding innovative ways to advance research is a key priority for PicnicHealth,” said Rachael Higgins, Chief Commercial Officer at PicnicHealth. “Life science companies have long faced challenges in generating meaningful evidence during the early launch phase, and we’re excited to announce this partnership to help bridge that gap.”
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
